Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

PRTA

Prothena Corporation plc

May 01 • 04:00PM ET

21.42

Dollar change +1.08
Percentage change 5.31	%

Healthcare • Biotechnology • Ireland • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VXF IWO IBB LABU VTWO SCHA VHT DFAS NUSC

Index	RUT	P/E	-	EPS (ttm)	-2.80	Insider Own	13.65%	Shs Outstand	53.68M	Perf Week	4.18%
Market Cap	1.15B	Forward P/E	-	EPS next Y	-4.10	Insider Trans	-0.20%	Shs Float	46.39M	Perf Month	-10.56%
Income	-147.03M	PEG	-	EPS next Q	-1.16	Inst Own	98.23%	Short Float	14.29%	Perf Quarter	-24.55%
Sales	91.37M	P/S	12.59	EPS this Y	-73.59%	Inst Trans	-4.11%	Short Ratio	10.30	Perf Half Y	-39.61%
Book/sh	10.46	P/B	2.05	EPS next Y	14.39%	ROA	-20.22%	Short Interest	6.63M	Perf Year	-60.19%
Cash/sh	11.54	P/C	1.86	EPS next 5Y	34.07%	ROE	-24.85%	52W Range	19.65 - 79.65	Perf YTD	-41.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.83%	ROI	-25.70%	52W High	-73.11%	Beta	0.30
Dividend TTM	-	Quick Ratio	11.24	Sales past 5Y	4680.14%	Gross Margin	77.94%	52W Low	9.01%	ATR (14)	1.21
Dividend Ex-Date	-	Current Ratio	11.24	EPS Y/Y TTM	-10.63%	Oper. Margin	-209.08%	RSI (14)	42.29	Volatility	5.64% 5.30%
Employees	173	Debt/Eq	0.02	Sales Y/Y TTM	69.50%	Profit Margin	-160.91%	Recom	1.44	Target Price	68.50
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-1169.13%	Payout	-	Rel Volume	1.10	Prev Close	20.34
Sales Surprise	-85.32%	EPS Surprise	-7.18%	Sales Q/Q	-99.37%	Earnings	Feb 15 AMC	Avg Volume	643.36K	Price	21.42
SMA20	-2.16%	SMA50	-14.31%	SMA200	-45.52%	Trades		Volume	708,995	Change	5.31%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $38
Dec-12-23	Initiated	Deutsche Bank	Buy	$62
Apr-24-23	Initiated	SVB Securities	Outperform	$80
Jan-27-23	Initiated	Piper Sandler	Overweight	$94
Nov-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$52 → $55
Sep-28-22	Upgrade	BofA Securities	Neutral → Buy
Nov-19-21	Initiated	JMP Securities	Mkt Outperform	$77
Jun-18-21	Upgrade	BofA Securities	Underperform → Neutral	$12 → $49
Jun-08-21	Reiterated	Oppenheimer	Outperform	$45 → $54
May-26-21	Initiated	Citigroup	Buy	$39
Feb-26-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$14 → $28
Feb-12-21	Upgrade	Jefferies	Hold → Buy	$15 → $30
Feb-02-21	Upgrade	BTIG Research	Neutral → Buy	$29
Dec-07-20	Initiated	H.C. Wainwright	Buy	$22
Jul-09-20	Upgrade	Oppenheimer	Perform → Outperform	$16
Nov-19-19	Upgrade	Evercore ISI	In-line → Outperform	$14
May-21-18	Downgrade	Barclays	Equal Weight → Underweight	$14 → $12
Apr-23-18	Downgrade	Jefferies	Buy → Hold
Apr-05-18	Reiterated	Barclays	Overweight	$70 → $50
Nov-20-17	Downgrade	Wedbush	Outperform → Neutral	$75 → $55

Show Previous Ratings

May-01-24 04:05PM	Prothena to Report First Quarter 2024 Financial Results on May 8 (Business Wire) +5.31%
Apr-25-24 10:01AM	Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline (Zacks)
Apr-15-24 04:05PM	Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma (Business Wire)
Mar-28-24 08:00AM	Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback (Investor's Business Daily)
Mar-05-24 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
04:05PM	Loading…
Mar-04-24 04:05PM	Prothena Appoints David Ford to Newly Created Chief People Officer Position (Business Wire)
Feb-21-24 04:05PM	Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate (Business Wire)
Feb-16-24 01:33PM	Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense (Zacks)
10:33AM	Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 04:50PM	Prothena: Q4 Earnings Snapshot (Associated Press Finance)
04:48PM	Prothena Corp PLC (PRTA) Reports 2023 Financial Results and Provides 2024 Outlook (GuruFocus.com)
04:05PM	Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-08-24 04:05PM	Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 (Business Wire)
Jan-24-24 11:02PM	Prothena Corp PLC Chief Accounting Officer Sells 5,000 Shares (GuruFocus.com)
Jan-10-24 12:06PM	Prothena's (PRTA) Update on Pipeline Progress Disappoints (Zacks) -9.46%
05:38AM	Loading…
05:38AM	Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
Jan-08-24 08:30AM	Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs (Business Wire) -13.23%
Dec-21-23 09:01AM	Prothena Corp PLC Chief Accounting Officer Sells Company Shares (GuruFocus.com)
Dec-17-23 05:41AM	These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank (TipRanks)
Dec-01-23 11:05AM	Insider Sell Alert: Karin Walker of Prothena Corp PLC Cashes Out 5,000 Shares (GuruFocus.com) +7.09%
Nov-29-23 08:35AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
Nov-20-23 06:00AM	FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success (Reuters)
Nov-17-23 01:35PM	Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market (Zacks)
08:15AM	Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning (Investor's Business Daily)
Nov-03-23 11:34AM	Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike (Zacks) +7.41%
Nov-02-23 07:03PM	Prothena Corp PLC (PRTA) Reports Q3 2023 Financial Results (GuruFocus.com)
06:25PM	Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates (Zacks)
05:24PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Oct-30-23 10:00AM	Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:09PM	Loading…
Oct-26-23 04:09PM	Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment (Investor's Business Daily) -14.62%
04:05PM	Prothena to Report Third Quarter 2023 Financial Results on November 2 (Business Wire)
10:02AM	Prothena (PRTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
05:02AM	Insider Sell: Karin Walker Sells 5,000 Shares of Prothena Corp PLC (GuruFocus.com)
Oct-18-23 11:20AM	5 Biotech Stocks Set to Outpace Q3 Earnings Estimates (Zacks)
Oct-17-23 07:57AM	Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock? (Zacks) -9.92%
Oct-16-23 11:54AM	UPDATE 1-Prothena prepares for potential sale - Bloomberg News (Reuters) +18.69%
11:42AM	Prothena preparing for a potential sale - Bloomberg News (Reuters)
Oct-12-23 05:01AM	Insider Sell: Brandon Smith Sells 4,000 Shares of Prothena Corp PLC (GuruFocus.com)
Oct-07-23 03:33PM	12 Stock Picks From Our Healthcare Roundtable Pros. Weight Loss Isnt the Only Big Deal in Medicine. (Barrons.com)
Oct-05-23 09:01AM	Insider Sell: Chief Regulatory Officer Carol Karp Sells 5,000 Shares of Prothena Corp PLC (GuruFocus.com)
Sep-28-23 05:01AM	Insider Sell: Prothena Corp PLC's Chief Legal Officer Michael Malecek Sells 5,000 Shares (GuruFocus.com)
Sep-19-23 09:01PM	Insider Sell: Karin Walker Sells 5,000 Shares of Prothena Corp PLC (GuruFocus.com)
Sep-14-23 01:32PM	Insider Sell: Chief Medical Officer Hideki Garren Sells 2,000 Shares of Prothena Corp PLC (GuruFocus.com)
Sep-07-23 12:00PM	Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why (Zacks)
Aug-31-23 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
Aug-04-23 09:13AM	Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates (Zacks) -7.30%
Aug-03-23 05:55PM	Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:49PM	Prothena: Q2 Earnings Snapshot (AP Finance)
04:05PM	Prothena Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire)
Aug-02-23 07:57AM	Prothena Corporation plc (NASDAQ:PRTA) Shares Could Be 36% Below Their Intrinsic Value Estimate (Simply Wall St.)
Jul-27-23 04:05PM	Prothena to Report Second Quarter 2023 Financial Results on August 3 (Business Wire)
Jul-18-23 05:36PM	The Fight Against Alzheimers Goes Beyond Plaque. Tangles Are a Target, Too. (Barrons.com)
05:36PM	The Fight Against Alzheimer Goes Beyond Plaque. Tangles Are a Target Too. (Barrons.com)
11:30AM	Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression (Zacks)
Jul-17-23 08:35AM	Prothena Presents New Research in the Treatment of Alzheimers Disease at Alzheimers Association International Conference® 2023 (AAIC®) (Business Wire)
Jul-13-23 09:22AM	Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment (Zacks)
Jul-11-23 04:05PM	Prothena to Present New Data from Alzheimers Disease Programs at Alzheimers Association International Conference® 2023 (AAIC®) (Business Wire)
08:59AM	Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY (Zacks)
Jul-10-23 04:10PM	Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody (Business Wire)
Jul-07-23 09:51AM	Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's (Zacks)
Jun-27-23 04:05PM	Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab (Business Wire)
Jun-12-23 09:25AM	Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement (Zacks) +5.05%
Jun-08-23 12:41PM	Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod (Zacks)
Jun-02-23 04:05PM	Prothena to Participate in Jefferies 2023 Healthcare Conference (Business Wire)
May-16-23 04:05PM	Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors (Business Wire)
May-10-23 06:13AM	Prothena Corporation plc (NASDAQ:PRTA) Analysts Just Trimmed Their Revenue Forecasts By 29% (Simply Wall St.)
May-05-23 12:27PM	Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates (Zacks) +12.02%
May-04-23 06:45PM	Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:39PM	Prothena: Q1 Earnings Snapshot (AP Finance)
04:05PM	Prothena Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
Apr-27-23 04:05PM	Prothena to Report First Quarter 2023 Financial Results on May 4 (Business Wire)
10:02AM	Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-24-23 04:05PM	Prothena to Participate in 2023 Bank of America Healthcare Conference (Business Wire)
Apr-18-23 02:34PM	Companies Like Prothena (NASDAQ:PRTA) Can Afford To Invest In Growth (Simply Wall St.)
Apr-14-23 07:30AM	Walgreens (WBA) Declares Partnership With Prothena Corporation (Zacks)
Apr-13-23 08:00AM	Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimers Disease Clinical Trial (Business Wire) +5.17%
Apr-06-23 01:49PM	Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue? (Zacks)
Mar-31-23 09:20AM	Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023 (Business Wire)
Mar-21-23 04:05PM	Prothena to Participate in Stifel 2023 Virtual CNS Days (Business Wire)
Mar-14-23 04:05PM	Prothena to Highlight Next Generation Treatments for Alzheimers and Parkinsons Disease at the AD/PD 2023 Meeting (Business Wire)
Mar-01-23 05:20AM	Analysts Just Made A Major Revision To Their Prothena Corporation plc (NASDAQ:PRTA) Revenue Forecasts (Simply Wall St.)
Feb-24-23 11:36AM	Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates (Zacks) +7.11%
Feb-23-23 04:05PM	Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-16-23 04:05PM	Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 (Business Wire)
Feb-05-23 05:03AM	TipRanks Perfect 10 List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks (TipRanks)
Feb-03-23 04:05PM	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-01-23 10:48AM	Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate (Benzinga) -5.09%
Jan-31-23 04:05PM	Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimers Disease (Business Wire)
Jan-15-23 09:01AM	Prothena (NASDAQ:PRTA) shareholder returns have been strong, earning 299% in 3 years (Simply Wall St.)
Dec-14-22 10:38PM	Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares (Business Wire) -8.32%
Dec-13-22 04:12PM	Prothena Announces Proposed Public Offering of Ordinary Shares (Business Wire)
Dec-12-22 11:30AM	Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022 (Business Wire) +5.47%
Nov-29-22 12:42PM	Biogen (BIIB) Down on Report of Death in Alzheimer's Study (Zacks)
Nov-22-22 10:07AM	Prothena (PRTA) Earns Milestone Payment From Novo Nordisk (Zacks)
Nov-21-22 04:05PM	Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy (Business Wire)
Nov-14-22 02:34PM	One Alzheimers drug has failed, but investors are still betting on Biogen and Lilly treatments (MarketWatch) +6.91%
Nov-09-22 06:07AM	Prothena Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -6.92%
Nov-07-22 09:11AM	Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth (Simply Wall St.)
Nov-04-22 11:13AM	Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y (Zacks) -5.43%

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Walker Karin L	Chief Accounting Officer	Jan 24 '24	Option Exercise	13.53	5,000	67,650	5,000	Jan 24 07:01 PM
Walker Karin L	Chief Accounting Officer	Jan 24 '24	Sale	34.00	5,000	170,000	0	Jan 24 07:01 PM
Walker Karin L	Chief Accounting Officer	Dec 20 '23	Option Exercise	13.53	5,000	67,650	5,000	Dec 20 07:17 PM
Walker Karin L	Chief Accounting Officer	Dec 20 '23	Sale	37.19	5,000	185,952	0	Dec 20 07:17 PM
Walker Karin L	Chief Accounting Officer	Nov 30 '23	Option Exercise	13.53	5,000	67,650	5,000	Nov 30 06:24 PM
Walker Karin L	Chief Accounting Officer	Nov 30 '23	Sale	34.00	5,000	170,000	0	Nov 30 06:24 PM
Walker Karin L	Chief Accounting Officer	Oct 25 '23	Option Exercise	13.53	5,000	67,650	5,000	Oct 25 08:03 PM
Walker Karin L	Chief Accounting Officer	Oct 25 '23	Sale	41.04	5,000	205,191	0	Oct 25 08:03 PM
Smith Brandon S.	Chief Operating Officer	Oct 11 '23	Option Exercise	11.12	4,000	44,480	4,000	Oct 11 08:25 PM
Smith Brandon S.	Chief Operating Officer	Oct 11 '23	Sale	46.75	4,000	186,985	0	Oct 11 08:25 PM
Karp Carol D.	Chief Regulatory Officer	Oct 04 '23	Option Exercise	12.15	5,000	60,750	5,000	Oct 04 07:52 PM
Karp Carol D.	Chief Regulatory Officer	Oct 04 '23	Sale	46.62	5,000	233,084	0	Oct 04 07:52 PM
Malecek Michael J	Chief Legal Officer	Sep 27 '23	Option Exercise	10.27	5,000	51,350	5,000	Sep 27 08:35 PM
Malecek Michael J	Chief Legal Officer	Sep 27 '23	Sale	47.38	5,000	236,885	0	Sep 27 08:35 PM
Walker Karin L	Chief Accounting Officer	Sep 19 '23	Option Exercise	15.04	5,000	75,200	5,000	Sep 19 05:37 PM
Walker Karin L	Chief Accounting Officer	Sep 19 '23	Sale	52.36	5,000	261,807	0	Sep 19 05:37 PM
Garren Hideki	Chief Medical Officer	Sep 13 '23	Option Exercise	24.90	2,000	49,800	2,000	Sep 13 07:33 PM
Smith Brandon S.	Chief Operating Officer	Sep 13 '23	Option Exercise	11.12	4,000	44,480	4,000	Sep 13 07:32 PM
Smith Brandon S.	Chief Operating Officer	Sep 13 '23	Sale	55.49	4,000	221,963	0	Sep 13 07:32 PM
Garren Hideki	Chief Medical Officer	Sep 13 '23	Sale	55.48	2,000	110,952	0	Sep 13 07:33 PM
Karp Carol D.	Chief Regulatory Officer	Sep 06 '23	Option Exercise	12.15	5,000	60,750	5,000	Sep 06 07:42 PM
Karp Carol D.	Chief Regulatory Officer	Sep 06 '23	Sale	54.76	5,000	273,804	0	Sep 06 07:42 PM
Malecek Michael J	Chief Legal Officer	Aug 30 '23	Option Exercise	10.27	5,000	51,350	5,000	Aug 30 07:24 PM
Malecek Michael J	Chief Legal Officer	Aug 30 '23	Sale	55.01	5,000	275,066	0	Aug 30 07:24 PM
Walker Karin L	Chief Accounting Officer	Aug 18 '23	Option Exercise	15.04	5,000	75,200	5,000	Aug 18 08:37 PM
Walker Karin L	Chief Accounting Officer	Aug 18 '23	Sale	57.18	5,000	285,922	0	Aug 18 08:37 PM
Garren Hideki	Chief Medical Officer	Aug 16 '23	Option Exercise	24.90	2,000	49,800	2,000	Aug 16 09:15 PM
Smith Brandon S.	Chief Operating Officer	Aug 16 '23	Option Exercise	11.12	4,000	44,480	4,000	Aug 16 09:15 PM
Smith Brandon S.	Chief Operating Officer	Aug 16 '23	Sale	58.71	4,000	234,844	0	Aug 16 09:15 PM
Garren Hideki	Chief Medical Officer	Aug 16 '23	Sale	58.74	2,000	117,480	0	Aug 16 09:15 PM
Karp Carol D.	Chief Regulatory Officer	Aug 02 '23	Option Exercise	12.15	5,000	60,750	5,000	Aug 02 09:00 PM
Zago Wagner M.	Chief Scientific Officer	Aug 02 '23	Option Exercise	12.15	4,000	48,600	4,000	Aug 02 09:00 PM
Karp Carol D.	Chief Regulatory Officer	Aug 02 '23	Sale	67.01	5,000	335,072	0	Aug 02 09:00 PM
Zago Wagner M.	Chief Scientific Officer	Aug 02 '23	Sale	67.05	4,000	268,182	0	Aug 02 09:00 PM
Malecek Michael J	Chief Legal Officer	Jul 26 '23	Option Exercise	10.27	5,000	51,350	5,000	Jul 26 07:45 PM
Malecek Michael J	Chief Legal Officer	Jul 26 '23	Sale	62.33	5,000	311,638	0	Jul 26 07:45 PM
Walker Karin L	Chief Accounting Officer	Jul 19 '23	Option Exercise	15.04	5,000	75,200	5,000	Jul 19 08:50 PM
Walker Karin L	Chief Accounting Officer	Jul 19 '23	Sale	69.19	5,000	345,943	0	Jul 19 08:50 PM
Garren Hideki	Chief Medical Officer	Jul 12 '23	Option Exercise	24.90	2,000	49,800	2,000	Jul 12 08:45 PM
Smith Brandon S.	Chief Operating Officer	Jul 12 '23	Option Exercise	11.12	4,000	44,480	4,000	Jul 12 08:45 PM
Smith Brandon S.	Chief Operating Officer	Jul 12 '23	Sale	67.51	4,000	270,026	0	Jul 12 08:45 PM
Garren Hideki	Chief Medical Officer	Jul 12 '23	Sale	67.51	2,000	135,027	0	Jul 12 08:45 PM
Karp Carol D.	Chief Regulatory Officer	Jul 05 '23	Option Exercise	12.15	5,000	60,750	5,000	Jul 05 09:33 PM
Zago Wagner M.	Chief Scientific Officer	Jul 05 '23	Option Exercise	12.15	4,000	48,600	4,000	Jul 05 09:32 PM
Karp Carol D.	Chief Regulatory Officer	Jul 05 '23	Sale	68.13	5,000	340,636	0	Jul 05 09:33 PM
Zago Wagner M.	Chief Scientific Officer	Jul 05 '23	Sale	68.16	4,000	272,648	0	Jul 05 09:32 PM
Selkoe Dennis J.	Director	Jul 03 '23	Option Exercise	11.33	5,000	56,650	7,845	Jul 03 06:16 PM
Selkoe Dennis J.	Director	Jul 03 '23	Sale	67.43	5,000	337,150	2,845	Jul 03 06:16 PM
Malecek Michael J	Chief Legal Officer	Jun 28 '23	Option Exercise	10.27	5,000	51,350	5,000	Jun 28 08:45 PM
Malecek Michael J	Chief Legal Officer	Jun 28 '23	Sale	69.82	5,000	349,118	0	Jun 28 08:45 PM
Garren Hideki	Chief Medical Officer	Jun 16 '23	Option Exercise	24.90	7,331	182,542	7,331	Jun 16 07:31 PM
Garren Hideki	Chief Medical Officer	Jun 16 '23	Sale	74.00	7,331	542,494	0	Jun 16 07:31 PM
Garren Hideki	Chief Medical Officer	Jun 14 '23	Option Exercise	24.90	4,669	116,258	4,669	Jun 14 09:15 PM
Smith Brandon S.	Chief Operating Officer	Jun 14 '23	Option Exercise	11.12	5,333	59,303	5,333	Jun 14 09:15 PM
Smith Brandon S.	Chief Operating Officer	Jun 14 '23	Sale	73.98	5,333	394,562	0	Jun 14 09:15 PM
Garren Hideki	Chief Medical Officer	Jun 14 '23	Sale	74.22	4,669	346,516	0	Jun 14 09:15 PM
Zago Wagner M.	Chief Scientific Officer	Jun 07 '23	Option Exercise	26.09	19,000	495,750	19,000	Jun 07 09:49 PM
Karp Carol D.	Chief Regulatory Officer	Jun 07 '23	Option Exercise	13.19	20,000	263,700	20,000	Jun 07 09:49 PM
Karp Carol D.	Chief Regulatory Officer	Jun 07 '23	Sale	71.05	20,000	1,421,009	0	Jun 07 09:49 PM
Zago Wagner M.	Chief Scientific Officer	Jun 07 '23	Sale	71.06	19,000	1,350,224	0	Jun 07 09:49 PM
Malecek Michael J	Chief Legal Officer	May 31 '23	Option Exercise	10.27	5,000	51,350	5,000	May 31 09:30 PM
Malecek Michael J	Chief Legal Officer	May 31 '23	Sale	64.64	5,000	323,223	0	May 31 09:30 PM
Walker Karin L	Chief Accounting Officer	May 19 '23	Option Exercise	15.04	5,000	75,200	5,000	May 19 09:31 PM
Walker Karin L	Chief Accounting Officer	May 19 '23	Sale	74.00	5,000	369,978	0	May 19 09:31 PM
Nguyen Tran	Chief Strategy Officer and CFO	May 17 '23	Option Exercise	26.15	95,000	2,483,950	98,200	May 17 09:53 PM
Kinney Gene G.	President and CEO	May 17 '23	Option Exercise	29.81	45,000	1,341,450	57,793	May 17 09:54 PM
Nguyen Tran	Chief Strategy Officer and CFO	May 17 '23	Sale	73.99	95,000	7,028,921	3,200	May 17 09:53 PM
Kinney Gene G.	President and CEO	May 17 '23	Sale	73.70	45,000	3,316,292	12,793	May 17 09:54 PM
Selkoe Dennis J.	Director	May 03 '23	Option Exercise	18.07	15,000	271,110	17,845	May 05 09:30 PM
Selkoe Dennis J.	Director	May 03 '23	Sale	57.00	15,000	855,000	2,845	May 05 09:30 PM

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc.

May 01 • 04:00PM ET

43.30

Dollar change +0.76
Percentage change 1.79	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

RARE Ultragenyx Pharmaceutical Inc. daily Stock Chart

Held by: VTI VB VXF VBK IBB SCHA IWP VHT IWF IWR

Index	-	P/E	-	EPS (ttm)	-8.33	Insider Own	6.45%	Shs Outstand	82.31M	Perf Week	-2.21%
Market Cap	3.57B	Forward P/E	-	EPS next Y	-4.99	Insider Trans	-1.83%	Shs Float	77.02M	Perf Month	-7.06%
Income	-606.64M	PEG	-	EPS next Q	-1.73	Inst Own	104.18%	Short Float	5.69%	Perf Quarter	-1.84%
Sales	434.25M	P/S	8.21	EPS this Y	22.64%	Inst Trans	-3.16%	Short Ratio	6.28	Perf Half Y	30.89%
Book/sh	3.35	P/B	12.94	EPS next Y	21.85%	ROA	-39.80%	Short Interest	4.38M	Perf Year	-1.66%
Cash/sh	7.03	P/C	6.16	EPS next 5Y	8.90%	ROE	-193.23%	52W Range	31.52 - 54.98	Perf YTD	-9.45%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.75%	ROI	-51.92%	52W High	-21.24%	Beta	0.68
Dividend TTM	-	Quick Ratio	2.49	Sales past 5Y	63.06%	Gross Margin	88.54%	52W Low	37.37%	ATR (14)	2.01
Dividend Ex-Date	-	Current Ratio	2.61	EPS Y/Y TTM	17.65%	Oper. Margin	-131.08%	RSI (14)	42.09	Volatility	3.38% 4.86%
Employees	1276	Debt/Eq	3.39	Sales Y/Y TTM	19.52%	Profit Margin	-139.70%	Recom	1.29	Target Price	89.52
Option/Short	Yes / Yes	LT Debt/Eq	3.24	EPS Q/Q	29.83%	Payout	-	Rel Volume	2.27	Prev Close	42.54
Sales Surprise	6.71%	EPS Surprise	10.98%	Sales Q/Q	23.27%	Earnings	May 02 AMC	Avg Volume	697.61K	Price	43.30
SMA20	-5.59%	SMA50	-9.07%	SMA200	2.81%	Trades		Volume	1,583,185	Change	1.79%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162
Jun-04-21	Resumed	Robert W. Baird	Neutral	$109
May-06-21	Upgrade	Evercore ISI	In-line → Outperform	$144
May-06-21	Upgrade	Citigroup	Neutral → Buy	$160 → $151
Apr-26-21	Resumed	Credit Suisse	Neutral	$99

Show Previous Ratings

Apr-30-24 04:00PM	Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease (GlobeNewswire)
08:00AM	Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
Apr-25-24 04:30PM	Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-19-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-16-24 11:33AM	Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study (Zacks)
07:30AM	Loading…
Apr-15-24 07:30AM	Ultragenyx says Angelman therapy is working, but safety questions remain (BioPharma Dive) -8.79%
07:00AM	Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 (GlobeNewswire)
Apr-12-24 04:22PM	Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome (GlobeNewswire) -7.30%
08:00AM	Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-22-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-24 08:11AM	10 NASDAQ Stocks with Biggest Upside (Insider Monkey)
Mar-12-24 05:00PM	Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ... (GuruFocus.com)
Mar-11-24 03:00PM	Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE) (GuruFocus.com)
Mar-08-24 09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
Feb-27-24 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire) +6.79%
04:05PM	Loading…
Feb-23-24 04:05PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-24 10:43AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.75%
10:35AM	Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
07:53AM	Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat (Zacks)
Feb-15-24 04:15PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-13-24 01:36PM	15 Best Strong Buy Stocks To Invest In (Insider Monkey) -5.91%
Feb-08-24 04:00PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-06-24 08:00AM	Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Feb-05-24 04:05PM	Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)
Jan-25-24 04:05PM	Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Jan-19-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 02:41PM	Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83 (Investor's Business Daily)
Jan-09-24 06:20PM	After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright (Zacks)
Jan-08-24 12:18PM	Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint (Zacks)
07:00AM	Loading…
07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Jan-07-24 11:00AM	Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones (GlobeNewswire)
Jan-04-24 08:12AM	Ultragenyx (RARE) Posts Update From AS Study of GTX-102 (Zacks)
08:00AM	Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Jan-03-24 08:00AM	Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome (GlobeNewswire)
Jan-02-24 04:05PM	Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 06:41PM	13 Most Promising Future Stocks To Buy According To Hedge Funds (Insider Monkey)
Dec-21-23 05:21PM	Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims (The Wall Street Journal)
04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-18-23 09:29AM	Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance Qualification (PPQ) Manufacturing of Novel Gene Therapy for Sanfilippo Syndrome (PR Newswire)
08:00AM	Ultragenyx Receives European Commission Decision for Evkeeza (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Dec-15-23 10:18AM	5 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Nov-20-23 04:30PM	Ultragenyx to Participate at Investor Conferences in November (GlobeNewswire)
Nov-17-23 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-23 05:00PM	Ultragenyx to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-23 01:12PM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks) +6.09%
Nov-02-23 06:26PM	Ultragenyx Pharmaceutical Inc (RARE) Reports Q3 2023 Earnings: Revenue Grows by 8% Year-Over-Year (GuruFocus.com)
04:36PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Oct-26-23 04:05PM	Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire) +5.12%
Oct-25-23 06:17AM	Insider Sell: CBO & EVP Thomas Kassberg Sells 39,878 Shares of Ultragenyx Pharmaceutical Inc (GuruFocus.com)
Oct-23-23 04:01PM	Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
04:01PM	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update (GlobeNewswire)
Oct-20-23 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-18-23 09:16PM	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -13.85%
Oct-17-23 04:02PM	Ultragenyx Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-16-23 08:00AM	Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease (GlobeNewswire) +10.28%
Oct-14-23 04:30PM	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-12-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.98%
Oct-09-23 08:00AM	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-05-23 08:00AM	Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023 (GlobeNewswire)
Sep-25-23 05:13PM	Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Sep-20-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-23 12:36PM	Is Ultragenyx Pharmaceutical (RARE) Too Good to Be True? A Comprehensive Analysis of a ... (GuruFocus.com) +6.06%
Aug-31-23 09:00AM	Ultragenyx to Participate at Investor Conferences in September (GlobeNewswire)
Aug-18-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-23 11:05AM	10 Oversold Healthcare Stocks to Buy (Insider Monkey)
Aug-11-23 11:14AM	Henrietta Lacks' estate sues Ultragenyx over Mass.-made gene therapies (American City Business Journals)
Aug-10-23 06:27PM	Henrietta Lacks' family sues Ultragenyx over use of HeLa cell line (Reuters)
Aug-08-23 07:11AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 41% Below Their Intrinsic Value Estimate (Simply Wall St.)
06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Aug-04-23 08:34AM	Q2 2023 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents) -8.79%
08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Aug-03-23 04:09PM	Ultragenyx: Q2 Earnings Snapshot (AP Finance)
04:00PM	Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Jul-31-23 08:00AM	Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Jul-27-23 05:00PM	Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
05:05AM	Can Mass. move beyond R&D to become a biomanufacturing leader? (American City Business Journals)
Jul-18-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-13-23 03:00PM	10 Best Revenue Growth Stocks to Buy (Insider Monkey)
Jul-12-23 08:00AM	Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy (GlobeNewswire)
Jul-07-23 07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks)
Jul-06-23 08:00AM	Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
Jun-28-23 11:06AM	This Biotech Stock Could Be a RARE Find (TheStreet.com)
Jun-21-23 08:00AM	Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts (GlobeNewswire)
Jun-20-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-09-23 10:55AM	13 Best Future Stocks for the Long-Term (Insider Monkey)
Jun-07-23 05:00PM	Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
03:21AM	4 big analyst picks: YEXT riding high (Investing.com)
Jun-05-23 04:00PM	Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-24-23 06:39AM	Strong week for Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders doesn't alleviate pain of three-year loss (Simply Wall St.)
May-19-23 08:30AM	Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit (GlobeNewswire)
May-18-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:15AM	Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing (Zacks)
May-17-23 08:00AM	Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S. (GlobeNewswire) +5.27%
May-15-23 02:43PM	Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating (Investor's Business Daily)
May-08-23 04:02PM	Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting (GlobeNewswire)
May-05-23 04:01PM	Ultragenyx to Present at Bank of Americas 2023 Health Care Conference (GlobeNewswire)

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Crombez Eric	EVP and Chief Medical Officer	Apr 18 '24	Sale	44.10	142	6,262	48,785	Apr 19 04:35 PM
Kassberg Thomas Richard	CBO & EVP	Mar 11 '24	Sale	49.93	11,509	574,644	252,823	Mar 12 01:41 PM
Fust Matthew K	Director	Mar 07 '24	Sale	50.88	12,195	620,443	14,860	Mar 11 12:54 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 01 '24	Sale	53.76	4,768	256,328	67,163	Mar 05 08:08 PM
Pinion John Richard	See Remarks	Mar 01 '24	Sale	53.76	4,173	224,340	89,268	Mar 05 08:15 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 01 '24	Sale	53.76	3,756	201,923	67,340	Mar 05 08:22 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 01 '24	Sale	53.76	1,238	66,555	48,927	Mar 05 08:10 PM
Kassberg Thomas Richard	CBO & EVP	Mar 01 '24	Sale	53.76	1,011	54,351	264,332	Mar 05 08:19 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 01 '24	Sale	53.76	341	18,332	41,380	Mar 05 08:13 PM
KAKKIS EMIL D	President & CEO	Feb 07 '24	Sale	45.00	30,000	1,350,000	539,770	Feb 08 03:49 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Jan 02 '24	Option Exercise	21.00	3,000	63,000	27,892	Jan 02 04:06 PM
KAKKIS EMIL D	President & CEO	Dec 29 '23	Sale	47.87	30,000	1,436,100	569,770	Jan 02 04:07 PM
Kassberg Thomas Richard	CBO & EVP	Oct 23 '23	Option Exercise	6.86	39,878	273,563	286,738	Oct 24 05:22 PM
Kassberg Thomas Richard	CBO & EVP	Oct 23 '23	Sale	32.78	39,878	1,307,201	246,860	Oct 24 05:22 PM
KAKKIS EMIL D	President & CEO	Oct 19 '23	Option Exercise	6.86	47,853	328,272	647,029	Oct 23 05:14 PM
KAKKIS EMIL D	President & CEO	Oct 19 '23	Sale	33.52	47,853	1,604,033	599,743	Oct 23 05:14 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 07 '23	Option Exercise	21.00	2,000	42,000	25,777	Sep 11 01:52 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 07 '23	Sale	40.80	2,163	88,249	23,614	Sep 11 01:52 PM
Harris Erik	EVP & Chief Commercial Officer	Sep 05 '23	Sale	37.96	6,000	227,760	51,281	Sep 06 05:51 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 01 '23	Sale	37.15	970	36,032	23,777	Sep 06 05:50 PM
Sanders Corazon (Corsee) D.	Director	Jun 30 '23	Sale	46.76	585	27,355	8,985	Jun 30 02:34 PM
Harris Erik	EVP & Chief Commercial Officer	Jun 19 '23	Sale	48.20	305	14,701	57,281	Jun 21 06:17 PM
Sanders Corazon (Corsee) D.	Director	Jun 08 '23	Sale	51.65	1,485	76,700	9,570	Jun 09 02:31 PM
Pinion John Richard	See Remarks	May 18 '23	Sale	50.00	2,012	100,600	74,744	May 19 01:54 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	May 09 '23	Option Exercise	21.00	3,000	63,000	30,747	May 10 08:09 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	May 04 '23	Sale	45.00	4,378	197,010	51,982	May 05 02:16 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PRTA

Prothena Corporation plc

RARE

Ultragenyx Pharmaceutical Inc.

Upgrade your FINVIZ experience